ClinicalTrials.gg
TerminatedNCT03052972Updated Sep 25, 2020Results posted

Flortaucipir 18F PET Imaging in BIOCARD Study

A Phase 1 interventional study of Flortaucipir F18 and Brain PET scan in Cognitive Decline, sponsored by Avid Radiopharmaceuticals. Terminated at 1 site in United States. Per ClinicalTrials.gov, last updated 2020-09-25.

Sponsored by Avid Radiopharmaceuticals (part of Eli Lilly and Company) · Phase 1, Interventional, and Diagnostic

Why this study was terminated
study terminated due to lower than expected enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
23
Allocation
Non-randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Cognitive Dysfunction by Eli Lilly and Company — 5 open to participants now, 8 under way, 2 of them phase 3. Cognitive Dysfunction · Eli Lilly and Company.

Enrollment
22nd of 22
23 · median 152
Started
2017
the only one that year
Phase 1
7 of 24
2 open now
Registered
11th of 24
by date

Among the 24 studies in Cognitive Dysfunction by Eli Lilly and Company, this one is the 22nd largest by enrollment of the 22 interventional ones that give a count, is the only one that started in 2017, is one of 7 in phase 1, and was the 11th registered.

Cognitive Dysfunction

3,878 studies on the registry are indexed under Cognitive Dysfunction; 1,120 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

5 of the 24 studies in Cognitive Dysfunction by Eli Lilly and Company are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 753 Cognitive Dysfunction studies recruiting now, 363 (48%) set no upper age limit and 143 (19%) stop at 75 or younger; 46 take children under 18; 261 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Cognitive Dysfunction by Eli Lilly and Company, or all of them as a file.
02

Study summary

This study is designed to assess the imaging characteristics of Flortaucipir (18F-AV-1451) in subjects who participated in the Biomarkers of Cognitive Decline Among Normal Individuals (BIOCARD) study at Johns Hopkins University.

03

Conditions studied

  • Cognitive Decline
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females that have provided consent and are currently enrolled in BIOCARD study
  • Ability to tolerate PET scan procedures
  • Ability to provide for study procedures

Exclusion criteria

Exclusion Criteria:

  • Has condition(s) that could augment risk to participant or compromise ability to tolerate experimental procedures or interfere with analysis of the study data as determined by the investigator
  • Has a history of risk factors for Torsades de Pointes or taking medications known to cause .
  • Has acquired prior to initial flortaucipir scan that clinically contradicts subject's participation in the study as determined by the investigator. Bazett's corrected QT (QTcB) interval must be assessed and not exceed accepted values (458 msec in males, 474 msec in females).
  • Females of who are not surgically sterile, not refraining from sexual activity, or not using reliable methods.
  • Has to flortaucipir
  • Has a currently infectious disease, endocrine/metabolic disease, pulmonary/renal/hepatic impairment, or cancer that could impact study participation or scan results in the opinion of the investigator.
  • Has a non-study related radiopharmaceutical imaging/treatment procedure within seven days prior to flortaucipir imaging visit.
  • Is unsuitable for a study of this type in the opinion of the investigator.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Amyloid Positive

    Clinically normal amyloid positive subjects from BIOCARD study receiving a flortaucipir PET scan

    Drug: Flortaucipir F18 · Procedure: Brain PET scan

  • Experimental
    Amyloid Negative

    Clinically normal amyloid negative subjects from BIOCARD study receiving a flortaucipir PET scan

    Drug: Flortaucipir F18 · Procedure: Brain PET scan

Interventions

  • 370 megabecquerel (MBq)(10 millicurie \[mCi\]) single dose

    Also known as: 18F-AV-1451, [F-18]T807, LY3191748, Tauvid

  • ProcedureBrain PET scan

    positron emission tomography (PET) scan of the brain

06

What researchers measure

Primary outcomes

  1. Qualitative Evaluation of Scan Results

    Subject scans were visually evaluated by an expert reader into three groups. Advanced Alzheimer's disease (AD) scan pattern = In either hemisphere, increased neocortical activity in the parietal/precuneus region(s), or frontal region(s) with increased uptake in the posterolateral temporal (PLT), parietal, or occipital region(s). Moderate AD scan pattern = In either hemisphere, increased neocortical activity limited to the PLT or occipital region(s). Not AD scan pattern = No increased neocortical activity, or increased neocortical activity isolated to the mesial temporal, anterolateral temporal, and/or frontal regions.

    Time frame: Baseline scan

  2. Quantitative Evaluation of Scan Results

    Standard Uptake Value Ratio (SUVr) by amyloid status using a weighted cortical average. For SUVr, a value of 1 or lower signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.

    Time frame: 75 minutes post dose administration

07

Results

Posted Aug 13, 2020
Limitations and caveats
Due to slower than expected enrollment, the study was terminated before 100 subjects were recruited.

Participant flow

Enrollment took place between Mar 2017 and Aug 2018 from the Biomarkers of Cognitive Decline Among Normal Individuals (BIOCARD) study

Participant flow — Overall Study
MilestoneAmyloid PositiveAmyloid Negative
Started185
Completed185
Not completed00

Outcome measures

PrimaryQualitative Evaluation of Scan Results

Subject scans were visually evaluated by an expert reader into three groups. Advanced Alzheimer's disease (AD) scan pattern = In either hemisphere, increased neocortical activity in the parietal/precuneus region(s), or frontal region(s) with increased uptake in the posterolateral temporal (PLT), parietal, or occipital region(s). Moderate AD scan pattern = In either hemisphere, increased neocortical activity limited to the PLT or occipital region(s). Not AD scan pattern = No increased neocortical activity, or increased neocortical activity isolated to the mesial temporal, anterolateral temporal, and/or frontal regions.

Time frame:
Baseline scan
Reported as:
Count of participants · Participants
Qualitative Evaluation of Scan Results
ParticipantsAmyloid PositiveAmyloid Negative
Advanced AD Scan Pattern (τAD++)110
Moderate AD Scan Pattern (τAD+)00
Not AD Scan Pattern (τAD-)65
PrimaryQuantitative Evaluation of Scan Results

Standard Uptake Value Ratio (SUVr) by amyloid status using a weighted cortical average. For SUVr, a value of 1 or lower signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.

Time frame:
75 minutes post dose administration
Reported as:
Mean · standardized uptake value ratio (SUVr)
Quantitative Evaluation of Scan Results
standardized uptake value ratio (SUVr)Amyloid PositiveAmyloid NegativeTotal
Quantitative Evaluation of Scan Results1.0414 ± 0.041651.0219 ± 0.020571.0371 ± 0.03854

Adverse events

Collected over AEs were collected at scan visits and for 48 hours after flortaucipir administration.. Non-serious events are listed at a 0.5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Amyloid Positive0/18 (0%)0/18 (0%)2/18 (11.1%)
Amyloid Negative0/5 (0%)0/5 (0%)0/5 (0%)
Most frequent other events
Most frequent other events
EventAmyloid PositiveAmyloid Negative
Abdominal pain upperGastrointestinal disorders1/180/5
DiarrhoeaGastrointestinal disorders1/180/5
HeadacheNervous system disorders1/180/5

Baseline characteristics

Age, Continuous
Age, Continuous(years)Amyloid PositiveAmyloid NegativeTotal
Mean72.1 ± 5.6966.8 ± 7.5370.9 ± 6.35
Sex: Female, Male
Sex: Female, Male(Participants)Amyloid PositiveAmyloid NegativeTotal
Female10414
Male819
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Amyloid PositiveAmyloid NegativeTotal
Hispanic or Latino112
Not Hispanic or Latino17421
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Amyloid PositiveAmyloid NegativeTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White18523
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Amyloid PositiveAmyloid NegativeTotal
United States18523
MMSE
MMSE(units on a scale)Amyloid PositiveAmyloid NegativeTotal
Mean29.3 ± 1.0229.2 ± 1.3029.3 ± 1.05
08

Study locations

1 site
  • Johns Hopkins Hospital
    Baltimore, Maryland 21205, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2017 to primary completion in Aug 2018, 16 months.

Results were first posted in Aug 2020, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2017
First posted
Feb 14, 2017
StartActual
Mar 23, 2017
Primary completionActual
Aug 14, 2018
CompletionActual
Aug 17, 2018
Results first posted
Aug 13, 2020
Last update
Sep 25, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03052972
Responsible party
Sponsor
First posted
Feb 14, 2017
Start date
Mar 23, 2017
Primary completion
Aug 14, 2018
Completion
Aug 17, 2018
Results posted
Aug 13, 2020
Last update
Sep 25, 2020

Study contacts

Medical Director
study chair · Avid Radiopharmaceuticals, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Flortaucipir

Start the discussion